Literature DB >> 11010825

Animal models for experimental tuberculosis.

D Smith1, E Wiegeshaus, V Balasubramanian.   

Abstract

Animal models for tuberculosis vaccine assays have evolved through a series of sequential experiments aimed at optimizing the activity of a particular vaccine product. As a result, studies that use different animal models do not agree on the potency ranking of antituberculosis vaccines, and each major test-system variable contributes to the disagreement. Disagreements among laboratories about the efficacy of vaccines are in part due to differences in test systems. A survey of potency assays of tuberculosis vaccines suggests that, based on the choice of a specific combination of variables in the test model, an investigator can show that any given vaccine product has superior potency. In view of these problems with animal models for research on tuberculosis vaccines, we recommend that attention should be focused on those animal models that replicate the key aspects of the natural history of human tuberculosis. The development of vaccines by means of new technologies requires animal models to assay the protective potency of vaccines that, ideally, inhibit tubercle bacilli at the point of infection. The development of new tuberculosis vaccines may be handled most efficiently in a joint venture that includes both laboratories involved in vaccine production and laboratories concerned with animal models.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11010825     DOI: 10.1086/314071

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  6 in total

1.  Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis.

Authors:  Susan L Kraft; Deanna Dailey; Matthew Kovach; Karen L Stasiak; Jamie Bennett; Christine T McFarland; David N McMurray; Angelo A Izzo; Ian M Orme; Randall J Basaraba
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

2.  Assessment of vaccine testing at three laboratories using the guinea pig model of tuberculosis.

Authors:  Ajay Grover; Jolynn Troudt; Kimberly Arnett; Linda Izzo; Megan Lucas; Katie Strain; Christine McFarland; Yper Hall; David McMurray; Ann Williams; Karen Dobos; Angelo Izzo
Journal:  Tuberculosis (Edinb)       Date:  2011-10-01       Impact factor: 3.131

3.  Aerosol infection of BALB/c mice with Brucella melitensis and Brucella abortus and protective efficacy against aerosol challenge.

Authors:  M M Kahl-McDonagh; A M Arenas-Gamboa; T A Ficht
Journal:  Infect Immun       Date:  2007-07-30       Impact factor: 3.441

4.  Granuloma transplantation: an approach to study mycobacterium-host interactions.

Authors:  Jeffrey S Harding; Heidi A Schreiber; Matyas Sandor
Journal:  Front Microbiol       Date:  2011-12-12       Impact factor: 5.640

5.  Bridging the Gap Between Validation and Implementation of Non-Animal Veterinary Vaccine Potency Testing Methods.

Authors:  Samantha Dozier; Jeffrey Brown; Alistair Currie
Journal:  Animals (Basel)       Date:  2011-11-29       Impact factor: 2.752

6.  A second-generation anti TB vaccine is long overdue.

Authors:  Mauricio Castañón-Arreola; Yolanda López-Vidal
Journal:  Ann Clin Microbiol Antimicrob       Date:  2004-06-03       Impact factor: 3.944

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.